Company: LGN
Filing Date: 2025-11-03
Form Type: DRS
Source: 0001193125-25-262782
Chunk: 332

Company: Legence Corp.
Filing Date: 2025-11-03
Form: DRS
Chunk 332
---
atives” for additional information on the Company’s interest rate swaps. |

| (2) | Includes right-of-use assets         
 acquired. See “Note 4—Acquisitions”. |

See “ Note 4—Acquisitions” for disclosure of non-cashfinancing of acquisitions through issuance of Parent interests. F-81

Confidential Treatment Requested by Legence Corp.

Pursuant to 17 C.F.R. Section 200.83

Note 16—Subsequent Events

The Company evaluated subsequent events through August 15, 2025, the date the Condensed Consolidated Financial Statements are available to
be issued. Refer to “” for interest rate swap agreements executed in July 2025. On July 4, 2025, the One Big Beautiful Bill Act (“the Act”) was enacted into law. The Act includes
significant changes to the U.S. tax code, including restoration of immediate recognition of domestic research and development expenditures and reinstatement of 100% bonus depreciation for qualifying property. The Act also removes the deductions
under Code Section 179D for energy-efficient commercial buildings, effective for properties where construction begins after June 30, 2026. Additionally, the Act eases the limitation on interest expense deductions by allowing companies to
calculate their income for 163(j) purposes before deducting depreciation and amortization. As the Act was enacted after the Company’s reporting period ended June 30, 2025, no adjustments have been made to the condensed consolidated
financial statements as of and for the three and six months ended June 30, 2025. The Company is currently evaluating the impact of the Act on its condensed consolidated financial statements, including the effects on its deferred tax assets and
liabilities. The impact of the Act will be reflected in the Company’s financial statements as of and for the three and nine months ending September 30, 2025, the period in which the legislation was enacted.

F-82

Confidential Treatment Requested by Legence Corp. Pursuant to 17 C.F.R. Section 200.83 Shares Legence Corp. Class A Common Stock Prospectus

, 2025

Confidential Treatment Requested by Legence Corp. Pursuant to 17 C.F.R. Section 200.83 PART II INFORMATION NOT REQUIRED IN PROSPECTUS Item 13. Other Expenses of Issuance and Distribution.

|                                   |     | Amount to Be 
 Paid         |   |
|:----------------------------------|:----|: